Richard Hazen

2.1k total citations
36 papers, 1.5k citations indexed

About

Richard Hazen is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Richard Hazen has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 22 papers in Virology and 16 papers in Molecular Biology. Recurrent topics in Richard Hazen's work include HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (10 papers). Richard Hazen is often cited by papers focused on HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (10 papers). Richard Hazen collaborates with scholars based in United States, United Kingdom and China. Richard Hazen's co-authors include Joseph Larner, Robert G. Ferris, Joseph H. Chan, Ronald J. Walkenbach, Edward P. Garvey, Lawrence R. Boone, D.K. Stammers, C. Webster Andrews, Karen R. Romines and Steven A. Short and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Richard Hazen

35 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Hazen United States 20 879 687 516 441 275 36 1.5k
Christophe Mathé France 16 507 0.6× 230 0.3× 578 1.1× 424 1.0× 203 0.7× 71 1.1k
Ernest Asante‐Appiah United States 21 655 0.7× 493 0.7× 958 1.9× 151 0.3× 293 1.1× 47 1.6k
David J. Neidhart United States 14 285 0.3× 226 0.3× 732 1.4× 213 0.5× 44 0.2× 17 1.3k
Blanda Stammen United Kingdom 12 505 0.6× 653 1.0× 420 0.8× 273 0.6× 195 0.7× 15 1.4k
Henry J. Breslin United States 17 756 0.9× 649 0.9× 519 1.0× 525 1.2× 150 0.5× 27 1.4k
Linda L. Wotring United States 22 233 0.3× 65 0.1× 632 1.2× 684 1.6× 223 0.8× 69 1.5k
Jinfa Du United States 18 631 0.7× 84 0.1× 677 1.3× 430 1.0× 430 1.6× 62 1.6k
Victor G. Matassa Italy 26 456 0.5× 129 0.2× 632 1.2× 653 1.5× 285 1.0× 60 1.8k
Michel Garneau Canada 21 289 0.3× 100 0.1× 495 1.0× 212 0.5× 339 1.2× 57 1.3k
Joel V. Tuttle United States 18 327 0.4× 52 0.1× 889 1.7× 154 0.3× 445 1.6× 22 1.3k

Countries citing papers authored by Richard Hazen

Since Specialization
Citations

This map shows the geographic impact of Richard Hazen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Hazen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Hazen more than expected).

Fields of papers citing papers by Richard Hazen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Hazen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Hazen. The network helps show where Richard Hazen may publish in the future.

Co-authorship network of co-authors of Richard Hazen

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Hazen. A scholar is included among the top collaborators of Richard Hazen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Hazen. Richard Hazen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ren, Jingshan, Philip P. Chamberlain, Anna Stamp, et al.. (2008). Structural Basis for the Improved Drug Resistance Profile of New Generation Benzophenone Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry. 51(16). 5000–5008. 64 indexed citations
2.
3.
McGuigan, Christopher, Sheila Srinivasan, Yikang Wang, et al.. (2006). Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives. Journal of Medicinal Chemistry. 49(24). 7215–7226. 51 indexed citations
4.
Miller, John F., C. Webster Andrews, Eric S. Furfine, et al.. (2006). Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385. Bioorganic & Medicinal Chemistry Letters. 16(7). 1788–1794. 70 indexed citations
5.
Lanier, E. Randall, Richard Hazen, Lisa Ross, Andrew L. Freeman, & Richard J. Harvey. (2005). Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.. PubMed. 39(5). 519–22. 10 indexed citations
6.
Miller, John F., Eric S. Furfine, Richard Hazen, et al.. (2005). Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorganic & Medicinal Chemistry Letters. 15(15). 3496–3500. 15 indexed citations
7.
Ferris, Robert G., Richard Hazen, M H St Clair, et al.. (2005). Antiviral Activity of GW678248, a Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrobial Agents and Chemotherapy. 49(10). 4046–4051. 51 indexed citations
8.
Sherrill, Ronald G., Eric S. Furfine, Richard Hazen, et al.. (2005). Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(15). 3560–3564. 8 indexed citations
9.
Chan, Joseph H., George A. Freeman, Jeffrey H. Tidwell, et al.. (2004). Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1. Journal of Medicinal Chemistry. 47(5). 1175–1182. 52 indexed citations
10.
Miller, John F., Eric S. Furfine, Mary H. Hanlon, et al.. (2004). Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorganic & Medicinal Chemistry Letters. 14(4). 959–963. 16 indexed citations
11.
Gudmundsson, Kristjan S., Zhicheng Wang, Susan M. Daluge, et al.. (2004). Phosphoramidate Protides of Carbocyclic 2′,3′‐Dideoxy‐2′,3′‐Didehydro‐7‐Deazaadenosine with Potent Activity Against HIV and HBV. Nucleosides Nucleotides & Nucleic Acids. 23(12). 1929–1937. 8 indexed citations
12.
Sherrill, Ronald G., C. Webster Andrews, Ronda G. Davis‐Ward, et al.. (2004). Optimization of pyrrolidinone based HIV protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(1). 81–84. 10 indexed citations
13.
Hopkins, Andrew L., Jingshan Ren, John Milton, et al.. (2004). Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.. Journal of Medicinal Chemistry. 47(24). 5912–5922. 73 indexed citations
14.
Hazen, Richard & E. Randall Lanier. (2003). Assessment of the Relative Potency of Emtricitabine and Lamivudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 34(2). 245–246. 2 indexed citations
15.
Stanley, Thomas B., et al.. (2002). Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening. Antiviral Research. 54(3). 149–162. 41 indexed citations
16.
Kazmierski, Wieslaw M., et al.. (1996). Inhibitors of Human Immunodeficiency Virus Type 1 Derived from gp41 Transmembrane Protein:  Structure−Activity Studies. Journal of Medicinal Chemistry. 39(14). 2681–2689. 10 indexed citations
17.
Faletto, M B, Wayne H. Miller, Edward P. Garvey, et al.. (1995). Unique purine crossover activation pathway for the potent anti-HIV agent 1592U89. Antiviral Research. 26(3). A262–A262. 3 indexed citations
18.
Abrahams, Sanders L., et al.. (1989). Trifenagrel: a chemically novel platelet aggregation inhibitor.. Journal of Pharmacology and Experimental Therapeutics. 249(2). 359–365. 51 indexed citations
19.
Walkenbach, Ronald J., Richard Hazen, & Joseph Larner. (1980). Hormonal regulation of glycogen synthase. Biochimica et Biophysica Acta (BBA) - General Subjects. 629(3). 421–430. 28 indexed citations
20.
Larner, Joseph, Peter J. Roach, Laura C. Huang, et al.. (1979). Hormonal Control of Glycogen Metabolism. Advances in experimental medicine and biology. 111. 103–123. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Mathé Breakdown of academic impact, for papers by Ernest Asante‐Appiah Breakdown of academic impact, for papers by David J. Neidhart Breakdown of academic impact, for papers by Blanda Stammen Breakdown of academic impact, for papers by Henry J. Breslin Breakdown of academic impact, for papers by Linda L. Wotring Breakdown of academic impact, for papers by Jinfa Du Breakdown of academic impact, for papers by Victor G. Matassa Breakdown of academic impact, for papers by Michel Garneau Breakdown of academic impact, for papers by Joel V. Tuttle
Rankless by CCL
2026